We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+50.72%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.13B
AUM Growth
+$173M
Cap. Flow
-$11.1M
Cap. Flow %
-0.99%
Top 10 Hldgs %
94.94%
Holding
19
New
1
Increased
6
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$7.22M
2
FLXN
Flexion Therapeutics, Inc.
FLXN
+$2.5M
3
IVTY
Invuity, Inc
IVTY
+$2.5M
4
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$1.48M
5
SPNC
Spectranetics Corp
SPNC
+$903K

Top Sells

Rank Stock Value
1
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$25.5M
2
ELDN icon
Eledon Pharmaceuticals
ELDN
+$711K

Sector Composition

Rank Sector Weight
1 Healthcare 69.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$654B
$240M 21.31%
2,155,100
– –
INGN icon
2
Inogen
INGN
$167M
$213M 18.88%
3,549,320
– –
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$167M 14.79%
3,610,487
– –
CLCD
4
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$120M 10.69%
3,156,563
+100,000
+3% +$1.48M
VGK icon
5
Vanguard FTSE Europe ETF
VGK
$30B
$102M 9.09%
2,101,000
– –
RETA
6
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$88.8M 7.88%
3,367,763
– –
CRVS icon
7
Corvus Pharmaceuticals
CRVS
$1.1B
$53M 4.71%
3,224,046
– –
XLRN
8
DELISTED
Acceleron Pharma
XLRN
$32.7M 2.91%
903,833
+217,970
+32% +$7.22M
SPNC
9
DELISTED
Spectranetics Corp
SPNC
$29M 2.58%
1,155,722
+38,720
+3% +$903K
MRUS
10
DELISTED
Merus
MRUS
$23.6M 2.1%
1,410,417
– –
FLXN
11
DELISTED
Flexion Therapeutics, Inc.
FLXN
$21.4M 1.9%
1,097,718
+147,557
+16% +$2.5M
IVTY
12
DELISTED
Invuity, Inc
IVTY
$17.6M 1.57%
1,285,448
+210,000
+20% +$2.5M
NBRV
13
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$7.87M 0.7%
4,467
+248
+6% +$478K
WMGIZ
14
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
0
– –
HTGM
15
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$2.91M 0.26%
7,112
– –
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.32B
$1.03M 0.09%
127,563
– –
OPK icon
17
Opko Health
OPK
$921M
$3K ﹤0.01%
+259
New +$2.58K
ELDN icon
18
Eledon Pharmaceuticals
ELDN
$276M
– –
-796
Closed -$711K
TBRA
19
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
– –
-2,027,091
Closed -$25.5M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q3 2016 Portfolio in Review

As of Q3 2016, Novo Holdings A/S held 19 positions worth $1.13B, up 18% from $953M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Novo Holdings A/S's Q3 2016 filing shows 1 new, 6 increased and 2 closed positions. Its largest new stake was Opko Health: 259 shares worth $3K. The largest sale was Tobira Therapeutics, Inc. Common Stock, an estimated $25.5M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 65% a quarter earlier.

  • Novo Holdings A/S's largest Q3 2016 buy was Opko Health: 259 shares worth $3K.
  • Novo Holdings A/S added most to Acceleron Pharma in Q3 2016, an estimated $7.22M increase.
  • Novo Holdings A/S fully exited Tobira Therapeutics, Inc. Common Stock in Q3 2016, selling an estimated $25.5M.
  • Novo Holdings A/S's ten largest holdings make up 95% of its $1.13B portfolio in Q3 2016.
  • Novo Holdings A/S opened 1 new position and closed 2 in Q3 2016.
  • Novo Holdings A/S's portfolio value rose 18% quarter-over-quarter to $1.13B.

Based on Novo Holdings A/S's 13F filing for Q3 2016, filed 14 Nov 2016.